Bausch + Lomb Q4 rev $1.17B (+18% YoY); guides FY 2024 rev $4.6-4.7B

Bausch & Lomb Corp

2023-FY EPS reported -$0.74 revenue$4,146,000,000

Q4 2023 revenue $1.173B (+18% YoY); full-year revenue $4.146B (+10% YoY).
GAAP net loss attributable to BLCO: Q4 $54M, FY $260M; prior year Q4 loss $1M, FY income $6M.
Adjusted EBITDA Q4 $231M (+$50M YoY); FY $738M (+$18M YoY). 2024 guidance: $840-$890M.
Pharmaceuticals segment revenue up 67% in Q4 driven by XIIDRA acquisition and MIEBO launch.
Cash flow from operations negative $17M for FY 2023 vs +$345M in 2022 due to inventory build and timing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Bausch & Lomb Corp reported financial results for the quarter and the year ended December 31, 2023.

Period: the quarter and the year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 21, 2024, Bausch + Lomb Corporation (the “Company”) issued a press release announcing results of operations for the quarter and the year ended December 31, 2023 and certain other financial information as of and for the quarter and the year ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

Bausch & Lomb Corp filing history →

Source: SEC EDGAR

accession 0001860742-24-000003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.